Omeros Corporation, a biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting inflammation, complement-mediated diseases, disorders of the central nervous system (CNS), and immune-related diseases. It provides OMIDRIA for use in cataract surgery or intraocular lens replacement in the United States.
Read More…
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryPharmaceuticals
SectorMedical
Phone206-676-5000
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$29.87 million
Profitability
Miscellaneous
Employees236
Next Earnings Date11/14/2019 (Estimated)
OptionableOptionable
Omeros (NASDAQ:OMER) Frequently Asked Questions
What is Omeros' stock symbol?
Omeros trades on the NASDAQ under the ticker symbol "OMER."
How were Omeros' earnings last quarter?
Omeros Co. (NASDAQ:OMER) announced its earnings results on Thursday, August, 8th. The biopharmaceutical company reported ($0.29) earnings per share for the quarter, topping the Thomson Reuters' consensus estimate of ($0.44) by $0.15. The biopharmaceutical company had revenue of $26.80 million for the quarter, compared to analysts' expectations of $25.33 million. The company's quarterly revenue was up 1476.5% compared to the same quarter last year. During the same period last year, the business earned ($0.70) EPS. View Omeros' Earnings History.
When is Omeros' next earnings date?
What price target have analysts set for OMER?
4 Wall Street analysts have issued 12-month price targets for Omeros' shares. Their predictions range from $18.00 to $35.00. On average, they expect Omeros' share price to reach $27.75 in the next year. This suggests a possible upside of 76.8% from the stock's current price. View Analyst Price Targets for Omeros.
What is the consensus analysts' recommendation for Omeros?
4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Omeros in the last year. There are currently 1 hold rating and 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Omeros.
What are Wall Street analysts saying about Omeros stock?
Here are some recent quotes from research analysts about Omeros stock:
- 1. According to Zacks Investment Research, "Omeros Corporation is a clinical-stage biopharmaceutical company committed to discovering, developing and commercializing products focused on inflammation and disorders of the central nervous system. Omeros' most clinically advanced product candidates are derived from its proprietary PharmacoSurgery(TM) platform designed to improve clinical outcomes of patients undergoing arthroscopic, ophthalmological, urological and other surgical and medical procedures. Omeros has four ongoing PharmacoSurgery(TM) clinical development programs, and its lead product candidate, OMS103HP, is being evaluated in Phase 3 clinical trials for use during arthroscopic surgery to improve postoperative joint function and reduce postoperative pain. Omeros is also building a diverse pipeline of preclinical programs targeting inflammation and central nervous system disorders. " (10/17/2019)
- 2. HC Wainwright analysts commented, "We note that the performance vs. consensus was substantially more impressive, as Omeros delivered top-line results that were $6M ahead of consensus estimates and bottom-line numbers that were $0.26 better than consensus. Management indicated on its earnings conference call the strong year-end performance of OMIDRIA, which is currently covered for nearly 90% of relevant lives and which is on a $100M annualized revenue run rate as of December 2018. Investors should note that we expect OMIDRIA revenue to meaningfully accelerate over the course of this year and well into 2020, with our full-year 2019 revenue projection currently at $165.4M and 2020 top-line revenue estimated at $242.3M. Given the strength of the OMIDRIA franchise and the potential for multiple near-term pipeline catalysts, notably the start of a possible regulatory filing in the U.S." (3/4/2019)
Has Omeros been receiving favorable news coverage?
Headlines about OMER stock have trended extremely negative recently, InfoTrie Sentiment Analysis reports. The research group identifies negative and positive press coverage by monitoring more than six thousand news and blog sources in real time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Omeros earned a daily sentiment score of -4.3 on InfoTrie's scale. They also assigned news headlines about the biopharmaceutical company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an impact on the company's share price in the near term. View News Stories for Omeros.
Who are some of Omeros' key competitors?
Some companies that are related to Omeros include Johnson & Johnson (JNJ), Merck & Co., Inc. (MRK), Pfizer (PFE), AbbVie (ABBV), Eli Lilly And Co (LLY), Bristol-Myers Squibb (BMY), Zoetis (ZTS), Allergan (AGN), Mylan (MYL), Perrigo (PRGO), Jazz Pharmaceuticals (JAZZ), Horizon Therapeutics (HZNP), The Medicines (MDCO), Nektar Therapeutics (NKTR) and Zogenix (ZGNX).
What other stocks do shareholders of Omeros own?
Who are Omeros' key executives?
Omeros' management team includes the folowing people:
- Dr. Gregory A. Demopulos, Co-Founder, Chairman, CEO & Pres (Age 60)
- Mr. Michael A. Jacobsen, Chief Accounting Officer, VP of Fin. & Treasurer (Age 61)
- Ms. Marcia S. Kelbon, VP of Patent, Gen. Counsel & Sec. (Age 59)
- Dr. Pamela Pierce Palmer, Co-Founder (Age 56)
- Dr. George A. Gaitanaris, Chief Scientific Officer & VP of Science (Age 62)
Who are Omeros' major shareholders?
Omeros' stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include Ingalls & Snyder LLC (10.19%), Cypress Capital Group (0.06%), Nisa Investment Advisors LLC (0.05%) and Wedbush Securities Inc. (0.02%). Company insiders that own Omeros stock include Marcia S Kelbon, Michael A Jacobsen and Thomas J Cable. View Institutional Ownership Trends for Omeros.
Which major investors are selling Omeros stock?
Which major investors are buying Omeros stock?
OMER stock was purchased by a variety of institutional investors in the last quarter, including Ingalls & Snyder LLC, Nisa Investment Advisors LLC and Cypress Capital Group. View Insider Buying and Selling for Omeros.
How do I buy shares of Omeros?
Shares of OMER can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is Omeros' stock price today?
One share of OMER stock can currently be purchased for approximately $15.70.
How big of a company is Omeros?
Omeros has a market capitalization of $773.85 million and generates $29.87 million in revenue each year. The biopharmaceutical company earns $-126,760,000.00 in net income (profit) each year or ($2.22) on an earnings per share basis. Omeros employs 236 workers across the globe.View Additional Information About Omeros.
What is Omeros' official website?
How can I contact Omeros?
Omeros' mailing address is 201 ELLIOT AVENUE WEST, SEATTLE WA, 98119. The biopharmaceutical company can be reached via phone at 206-676-5000.
MarketBeat Community Rating for Omeros (NASDAQ OMER)
MarketBeat's community ratings are surveys of what our community members think about Omeros and other stocks. Vote "Outperform" if you believe OMER will outperform the S&P 500 over the long term. Vote "Underperform" if you believe OMER will underperform the S&P 500 over the long term. You may vote once every thirty days.
